amphotericin b liposome / Generic mfg. - LARVOL DELTA

Successful Allogeneic Hematopoietic Stem Cell Transplantation for AML with Pulmonary Mucormycosis under Isavuconazole. (PubMed, J Infect Chemother) - "Although liposomal amphotericin B (≥ 5 mg/kg) administration following complete surgical resection is recommended, many cases remain incurable. A 70-year-old man with FLT3-ITD mutated acute myeloid leukemia achieved complete remission after the second induction therapy with gilteritinib...To the best of our knowledge, this is the first reported case of ISCZ treatment in an allo-HCT patient with unresectable IPM. ISCZ could be a safe and effective anti-Mucorales therapy in the allo-HCT setting."

Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Transplantation • FLT3

Clinical impact of fluconazole-resistant Candida parapsilosis: a narrative review. (PubMed, Future Microbiol) - "Treatment options are limited: echinocandins and liposomal amphotericin B (L-AmB) are commonly used alternatives, but their use is challenged by intrinsic and emerging echinocandin resistance and L-AmB toxicity and cost. Novel agents such as rezafungin, fosmanogepix, and ibrexafungerp have shown promising activity against fluconazole-resistant C. parapsilosis, though further clinical studies are needed to confirm their efficacy. This narrative review aims to summarize current evidence on the epidemiology, clinical implications, and therapeutic approaches for fluconazole-resistant C. parapsilosis infections."

Journal • Review • Infectious Disease

Disseminated Musculoskeletal Coccidioidomycosis in an Immunocompetent Host: A Rare Case Requiring Extensive Spinal and Pelvic Surgery. (PubMed, Cureus) - "Despite antifungal therapy, his disease progressed, necessitating escalation of treatment from fluconazole to isavuconazole and liposomal amphotericin B, followed by initiation of fosmanogepix as part of the approved treatment regimen. This case highlights the importance of high clinical suspicion, aggressive surgical intervention, and multidisciplinary management in complex disseminated coccidioidomycosis, even in immunocompetent hosts."

Journal • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Respiratory Diseases

Fever of Unknown Origin With Severe Hepatosplenomegaly in an Immunocompetent Female (ACG 2025) - "The patient was started on liposomal amphotericin B and her fever resolved within 3 days of treatment. She was switched to oral itraconazole therapy after 2 weeks and there has been no recurrence of fever...Clinicians should have high suspicion for histoplasmosis in patients with both fever of unknown origin and HSM. Thorough history-taking should include exposure to soil and bird droppings."

Anemia • Cardiovascular • Cytomegalovirus Infection • Diabetes • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Influenza • Metabolic Disorders • Pneumonia • Pulmonary Embolism • Respiratory Diseases • Rheumatology

Unexpected Cause of Acute Gastrointestinal Bleeding: Disseminated Histoplasmosis of the Gastrointestinal Tract (ACG 2025) - "The patient was treated with 14 days of liposomal amphotericin B, followed by itraconazole and antiretroviral therapy, with resolution of bleeding and stabilization of hemoglobin. Histoplasmosis with GI involvement occurs about 70-90% of time in patients with AIDS. Outcomes are favorable with timely treatment using liposomal amphotericin followed by itraconazole for 12 months. This case highlights the unusual presentation and it can help clinicians broaden their differentials when evaluating GI bleeding in HIV patients."

Anemia • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma

A Rare Complication of TNF-α Inhibitor With Histoplasmosis Associated Necrotizing Granulomatous Hepatitis (ACG 2025) - "Clinical presentation includes fever, malaise, jaundice, abdominal pain, and cholestatic liver enzyme abnormalities.Case Description/ A 62-year-old man from Mexico with rheumatoid arthritis, previously on infliximab, was admitted with abdominal pain...He was readmitted and started on liposomal amphotericin B. His anti-tuberculosis regimen was consolidated. Fluconazole was stopped...He was discharged with itraconazole for 12 months. Histoplasmosis associated necrotizing granulomatous hepatitis is a rare complication in patients on tumor necrosis factor-α inhibitor...Necrotizing granuloma (H&E)Figure 2B. Histoplasma microorganisms (PAS)"

Fatigue • Gastroenterology • Gastrointestinal Disorder • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Tuberculosis

Laryngeal Cryptococcosis in the Setting of Dupilumab Treatment: A Case Report (AAO-HNSF 2025) - "At that time, he was treated with a 14-day course of Bactrim for possible bacterial laryngitis...After ruling out disseminated infection, our patient was successfully treated with liposomal amphotericin B and a prolonged course of fluconazole... Our case represents an exceedingly unique situation in which an already rare disease presentation is coupled with a background of immunomodulation with Dupilimab. While prior studies have reported rare cryptococcal infections in patients on inhaled corticosteroids, the role of Dupilumab in cryptococcal infections has not been explored. Further research is warranted to explore the relationship between dupilumab and susceptibility to fungal infections."

Case report • Clinical • Asthma • Chronic Cough • Cough • Dermatology • Dermatopathology • Dysphonia • Immunology • Infectious Disease • Otorhinolaryngology • Rare Diseases • Respiratory Diseases • IL13 • IL4

Non-dermatophytic mold onychomycosis mimicking subungual malignant tumour (ECP 2025) - "The patient responded satisfactorily to treatment with i.v. liposomal amphotericin B (4 mg/kg/d) for ten days followed by surgical debulking of the subungual mass and a three-month course of p.o. voriconazole (200 mg b.i.d.)... Non-dermatophyte molds may be involved in onychomycosis as primary pathogens in up to 2.3% of all onychomycoses, or as contaminant agents. Acremonium spp. in particular, is an uncommon cause of onychomycosis, especially in immunocompetent individuals."

Dermatology • Human Immunodeficiency Virus • Infectious Disease • Melanoma • Mood Disorders • Oncology • Solid Tumor • Squamous Cell Carcinoma

Invasive Gastric Mucormycosis With Concomitant Cytomegalovirus (CMV) and Herpes Simplex Virus (HSV) Gastritis: A Rare Complication of Immunosuppression (ACG 2025) - "He was started on a multi-drug antifungal regimen including liposomal amphotericin B, micafungin, posaconazole and intravenous ganciclovir.Despite aggressive medical therapy, the patient continued to deteriorate and then decided to transition to hospice care. Invasive fungal infections involving the gastrointestinal (GI) tract are exceedingly rare and predominantly occur in immunosuppressed individuals. This case illustrates the complexity and severity of polymicrobial gastric infections in immunocompromised hosts and the importance of early endoscopic/histologic evaluation in cases with gastrointestinal symptomatology.Figure: One oozing small gastric ulcer with rolled margins was found on the anterior wall of the stomach. Figure: One oozing cratered very large gastric ulcer was found in the proximal gastric body."

Acute Kidney Injury • B Cell Lymphoma • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Herpes Simplex • Infectious Disease • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Peptic Ulcer • Renal Disease • Respiratory Diseases

Comparative study of liposomal amphotericin B, posaconazole, and micafungin for primary antifungal prophylaxis in pediatric patients with acute leukemia. (PubMed, J Cancer Res Clin Oncol) - "We found a significant difference in efficacy between the three antifungal prophylaxis regimens. In our study, micafungin achieved the lowest IFD breakthrough rate. However, multicenter clinical studies would be needed to confirm the results."

Clinical • Journal • Observational data • Retrospective data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Transplantation

Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases (clinicaltrials.gov) - P=N/A | N=36 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New trial • Hematological Malignancies • Infectious Disease

Pulmonary Mucormycosis in Diabetic Patients: A Case Series From a Tertiary Respiratory Center in Sri Lanka. (PubMed, Cureus) - "Two patients were successfully treated with prolonged intravenous liposomal amphotericin B therapy...This series underscores the importance of early clinical suspicion and tissue diagnosis in suspected invasive fungal infections among diabetic patients. In resource-limited and endemic settings, timely recognition and intervention remain crucial for improving patient outcomes."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Pathologically Confirmed Dual Coronavirus Disease 2019-Associated Tracheobronchial Aspergillosis and Pulmonary Mucormycosis in a Non-Endemic Region: A Case Report. (PubMed, J Clin Med) - "Given the patient's risk factors and clinical features, liposomal amphotericin B therapy was initiated... This case highlights the critical need for heightened clinical suspicion of combined invasive fungal infections in severely immunocompromised patients with COVID-19, even in non-endemic regions for mucormycosis. Early tissue-based diagnostic interventions and prompt initiation of optimal antifungal therapy are essential for obtaining ideal outcomes when co-infection is suspected."

Journal • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplantation

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis (clinicaltrials.gov) - P2 | N=101 | Active, not recruiting | Sponsor: Drugs for Neglected Diseases | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2025 ➔ Dec 2025 | Trial primary completion date: Jan 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease

Lymphatic-targeted amphotericin B nanocrystals delivered using microarray patches applied to cutaneous leishmaniasis. (PubMed, J Control Release) - "In vivo rat studies revealed MAPs achieved 3.2-fold and 2.8-fold higher AmB accumulation in axillary and lumbar lymph nodes, respectively, compared to the commercial formulation IV AmBisome® (p < 0.05). Reduced liver, spleen and kidney accumulation suggests lower organ toxicity. AmB-NCs MAPs present a promising, minimally invasive alternative for CL treatment, enhancing lymphatic targeting while reducing healthcare burdens, addressing key barriers to effective treatment."

Journal • Dermatology • Infectious Disease

Cutaneous leishmaniasis in a renal transplant patient: Diagnostic challenges in a non-endemic setting. (PubMed, IDCases) - "Initially suspected to be cutaneous tuberculosis or malignancy, investigations, including a skin biopsy, revealed cutaneous leishmaniasis. The patient responded well to treatment with liposomal amphotericin B, highlighting the importance of considering leishmaniasis in differential diagnoses, especially in immunocompromised individuals from, or travelling to, endemic regions."

Journal • Dermatology • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Transplantation • Tuberculosis

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) (clinicaltrials.gov) - P3 | N=428 | Not yet recruiting | Sponsor: Duke University | Trial completion date: Jan 2032 ➔ Jul 2031 | Trial primary completion date: Jan 2030 ➔ Jul 2030

Trial completion date • Trial primary completion date

Acute lymphoblastic leukemia with Fusarium solani infection: a case report. (PubMed, Front Med (Lausanne)) - "Treatment included systemic voriconazole, local debridement, topical liposomal amphotericin B, G-CSF for neutrophil recovery, and psychological intervention for anxiety. Unusual skin lesions in immunocompromised patients, especially those with hematological malignancies receiving chemotherapy, warrant high suspicion for Fusarium infection. Timely microbiological diagnosis and early initiation of combined systemic-topical antifungal therapy, alongside neutrophil support and multidisciplinary care, are critical for improving outcomes."

Journal • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Mood Disorders • Oncology • Psychiatry

Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial. (PubMed, Clin Infect Dis) - P2 | "Reduced flucytosine dose of 60 mg/kg/day for 10 days demonstrated inferior efficacy in CSF fungal clearance. These findings support further investigation of dose optimization strategies."

Journal • CNS Disorders • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Leukopenia

Mucosal Leishmaniasis: From Diagnosis to New Treatment Perspectives (AAO-HNSF 2025) - "Stage I: Nodulation in the nasal septum mucosa; Stage II: Fine-grained superficial ulceration; Stage III: Deep-grained ulceration; Stage IV: Nasal septum perforation and Stage V: Destruction of the nasal pyramidAntimonial therapy remains the first-line therapy for ML across South and Central American countries due to the high cost of liposomal amphotericin B. However, this drug is associated with numerous adverse effects and contraindications.In the last two decades, newer and more effective therapies have been increasingly utilized for CL and ML, including amphotericin B, pentamidine, miltefosine, and combinations of antimony with other agents such as pentoxifylline or granulocyte/macrophage colony-stimulating factor. THIS MAKES AN EARLY DIAGNOSIS OF THE DISEASE NECESSARY. IN ADDITION TO DEMONSTRATING NEW TREATMENT ALTERNATIVES AS EARLY AS POSSIBLEComprehensive Otolaryngology Track Statement :"

Dermatology • Infectious Disease • Otorhinolaryngology

Case Report: Visceral leishmaniasis misdiagnosed as systemic lupus erythematosus in a 36-year-old migrant worker. (PubMed, Front Med (Lausanne)) - "Treatment with liposomal amphotericin B led to prompt clinical resolution. This case highlights the importance of obtaining travel history and considering parasitic infections in patients with refractory fever and splenomegaly."

Journal • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Candida auris infection at a pediatric burn center: Treatment and infection control measures. (PubMed, North Clin Istanb) - "Collaboration between clinical microbiology laboratories and the IPC committee is essential for making correct and early diagnosis, optimizing the management of precautions and reducing the spread of infection in the hospital."

Journal • Infectious Disease • Pediatrics

Mycotic arthritis of the knee caused by Arthrographis kalrae in an immunocompetent child: A case report and litterature review. (PubMed, Diagn Microbiol Infect Dis) - "After anterior synovectomy and three revisions for surgical washout, the child was treated by liposomal amphotericin B for 5 days and voriconazole for 6 months. Management typically involves a combination of antifungal treatments and surgical interventions in 55 % of case. Prognosis depending on the site and extent of the infection, but is often poor, with complete recovery achieved in only 50 % of reported cases."

Journal • Immunology • Infectious Disease • Rheumatology

The story of elimination of visceral leishmaniasis (kala-azar) in India-Challenges towards sustainment. (PubMed, PLoS Negl Trop Dis) - "In 2005, the Kala-azar Elimination Program (KAEP) was launched jointly by India, Bangladesh, and Nepal, with treatment initially with oral miltefosine, succeeded later by single-dose liposomal amphotericin B (AmBisome), and in 2023, India achieved the goal of kala-azar elimination, defined as an incidence below 1 per 10,000 at sub-district (block) level...Active case detection, early diagnosis, and prompt, complete treatment are required to prevent fresh transmission. Periodic updates of health personnel, community awareness, and continued availability of the theragnostics are important steps for early detection and containment of an outbreak."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Malaria

Utility and Pitfalls of β-D-Glucan for Diagnosis and Response Monitoring of Chronic Disseminated Candidiasis in Paediatric Cancer Patients. (PubMed, Mycoses) - "BDG in serum is useful for microbiological diagnosis and monitoring of probable CDC; however, it remains a non-specific fungal biomarker whose results need to be scrutinised in patients who do not respond to treatment as expected."

Biomarker • Journal • Acute Lymphocytic Leukemia • Candidiasis • Dermatology • Ewing Sarcoma • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sarcoma • Solid Tumor